Please assess the completion status of the following clinical trial:

Trial Title: CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Symptomatic multiple myeloma~* Previously treated disease meeting one of the following criteria:~  * Have light-chain amyloidosis that has been treated with at least one prior regimen~ * Symptomatic (relapsed or refractory) multiple myeloma~    * Patients must have received 1-3 treatment regimens~   * Induction therapy followed by autologous stem cell transplantation and consolidation considered one regimen~* Measurable disease, as defined by 1 of the following:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * More than 200 mg of monoclonal protein in the urine on 24-hour electrophoresis~ * Serum immunoglobulin free light chain (FLC) \> 10 mg/dL and an abnormal FLC ratio~ * Measurable soft tissue plasmacytoma, not previously irradiated~ * More than 30% plasma cells in bone marrow~* At least 10% plasma cells as measured by bone marrow aspirate, bone marrow biopsy, or labeling index~* No monoclonal gammopathy of undetermined significance (not applicable for patients with amyloid)~* No smoldering myeloma (not applicable for patients with amyloid)~PATIENT CHARACTERISTICS:~* ECOG performance status 0, 1, or 2~* ANC ≥ 1,000/μL~* Platelet count ≥ 75,000/μL~* Creatinine ≤ 2.5 mg/dL~* Not pregnant or nursing~  * Women must refrain from breastfeeding during study participation and for at least 28 days after discontinuation of study drug~* Negative pregnancy test~* Fertile female patients must use two reliable forms of contraception simultaneously at least 28 days before beginning, during, and at least 28 days after completion of study drug~  * The two methods of reliable contraception must include one highly effective method (i.e., intrauterine device \[IUD\], hormonal \[birth control pills, injections, or implants\], tubal ligation, or partner's vasectomy) and one additional effective (barrier) method (i.e., latex condom, diaphragm, or cervical cap)~* Fertile male patients must use a latex condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 28 days after stopping treatment~* Men must agree to abstain from donating semen or sperm during study participation and for 28 days after discontinuation of study drug~* Willing to abstain from donating blood during study participation and for 28 days after discontinuation of study drug~* No uncontrolled infection~* No other active malignancy~* No New York Heart Association class III or IV cardiac disease (all patients)~  * Serum troponin T \> 0.10 ng/mL (amyloid patients only)~* No known positivity for HIV or active hepatitis infection~* No active deep vein thrombosis or pulmonary embolism that has not been therapeutically anticoagulated~* No condition, including the presence of laboratory abnormalities, that places the patient at unacceptable risk for participating in the study or confounds the ability to interpret data from the study~* No known hypersensitivity to thalidomide or lenalidomide including development of erythema nodosum if characterized by a desquamating rash~* No peripheral neuropathy \> grade 2~PRIOR CONCURRENT THERAPY:~* All previous cancer therapy, including chemotherapy and investigational agents, must have been discontinued ≥ 2 weeks prior to study registration~* No radiotherapy ≤ 14 days prior to study registration~* No other concurrent anti-myeloma therapy~* No concurrent radiotherapy, except for palliation of a single painful bone lesion or fracture~* Routine concurrent bisphosphonate therapy allowed for patients with myeloma bone disease~* Willing and able to take aspirin or alternate prophylactic anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Relapsed Myeloma (<4 Prior Regimens) (Type: EXPERIMENTAL): Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Lenalidomide Refractory Myeloma (Type: EXPERIMENTAL): Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Bortezomib/Lenalidomide Refractory/Relapsed Myeloma (Type: EXPERIMENTAL): Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Bortezomib/Lenalidomide Relapsed/Refractory Myeloma (Type: EXPERIMENTAL): Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Relapsed Myeloma (< 4 Prior Regimens) (Type: EXPERIMENTAL): Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Relapsed/Refractory Myeloma (Type: EXPERIMENTAL): Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle
- Relapsed Amyloidosis (Type: EXPERIMENTAL): Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).